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Aims and method To assess the benefits of the introduction of routine vitamin D
serum sampling for all patients admitted to a secure in-patient hospital in the North
of England providing medium security, low security and rehabilitation services for
offenders with intellectual and developmental disability. The vitamin D levels of 100
patients were analysed at baseline. Those with insufficient or deficient levels were
offered treatment and retested after 1 year. Vitamin D levels were analysed in the
context of level of security, seasonality of test and co-prescription of psychotropic
medications.
Results Eighty-three per cent of patients had suboptimal vitamin D levels at initial
test (41% deficient and 42% insufficient). This was seen among established patients
and new admissions. Regression analysis of baseline vitamin D levels revealed no
differences for levels of security, seasonality, whether patients were taking
antipsychotic or anticonvulsant medication, or length of stay. Patients with deficiency
or insufficiency were all offered supplementation. Those who opted in had
significantly higher vitamin D levels at follow-up, compared with those who declined
treatment.
Clinical implications Established and newly admitted patients in our secure mental
health services had substantial levels of vitamin D insufficiency. In the light of the
morbidities that are associated with deficient vitamin D levels, routine screening and
the offer of supplementation is advisable.
Declaration of interest None.
Background
Suboptimal levels of plasma 25-hydroxy vitamin D (25OHD)
have been implicated in a number of morbidities, including
musculoskeletal and cardiorespiratory diseases, diabetes
and depression.1,2 A substantial proportion of vitamin D is
obtained from ultraviolet-B light acting on the skin1, although
the relative amounts obtained from solar and food sources
vary from study to study.3 There is, therefore, a greater poten-
tial for impaired vitamin D levels during the autumn and
winter months.4 Public Health England currently advise a
minimum of 10 mg of vitamin D per day for the general popu-
lation, but give no separate advice for those at risk of minimal
sunlight exposure, such as institutionalised individuals.5
It is estimated that approximately 50% of the popula-
tion of Northern England have insufficient or deficient vita-
min D levels.6 Based on National Health Service guidelines,
in January 2013, a decision was made by the clinicians at
Northgate Hospital, Northumberland, UK, to routinely
screen for vitamin D deficiency and treat as necessary.7
Northgate Hospital has a range of levels of secure care
facilities for people with intellectual and developmental
disabilities (IDD) who offend, as well as providing specialised
services for people with severe autism spectrum disorders.
This paper describes an evaluation of the results of
screening for 25OHD at Northgate Hospital. It was hypothe-
sised that patients in secure services would have suboptimal
levels of 25OHD due to less exposure to sunlight, and as a
possible consequence of medications prescribed for mental
disorders. We were also interested in the effect of season
of testing, and whether the decision to routinely screen for
and treat 25OHD deficiency would lead to improvement in
any such deficiencies.
Aims
1 To describe vitamin D levels in an ‘at risk’ population of
offenders with IDD in secure care, across a range of levels
of security;
2 To assess the effectiveness of screening for and treating
any vitamin D deficiencies.
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Method
Cohort 1
Between January 2013 and February 2014, all patients at
Northgate Hospital were screened for vitamin D deficiency.
These existing patients, who were having blood tests taken
as part of their annual health checks over the year, had a
serum vitamin D level added to the standard biochemistry
request form with no additional venepuncture over and
above routine testing.
Cohort 2
While existing patients were having their vitamin D levels
checked as part of annual health checks, new admissions
to the secure services were also being screened. Because
we judged that there may be differences between the estab-
lished patient group and new admissions (higher levels of
sun exposure, dietary intake differences), new admissions
from January 2013 onwards were considered as a separate
cohort for the purpose of assessing baseline vitamin D levels.
Data were collected for the first 100 patients screened,
from both cohorts. The results were classified according to
standard biochemical reference ranges for total 25OHD
(the sum of 25OHD2 and 25OHD3):
• deficient (<25 nmol/L)
• insufficient (25–49 nmol/L)
• sufficient (50–75 nmol/L)
• optimal (>75 nmol/L) vitamin D levels.
Each result was stored with anonymised data about the
patient’s age, length of stay prior to the initial test,
co-prescribed psychotropic medications, level of in-patient
security and the season the test was performed.
Following the initial test, all patients were offered
appropriate treatment by the hospital’s physical health
service if required, although not all patients accepted it.
At Northgate Hospital, the supplementation protocol for
vitamin D is based on guidance provided by the National
Health Service Specialist Pharmacy Service.8 Those patients
found to be deficient were treated with 20 000 units of oral
colecalciferol twice weekly for 8 weeks and then maintained
on 800 units daily. Those found to have insufficient levels
were treated with a maintenance dose of 800–1600 units
of oral colecalciferol daily. Patients’ 25OHD levels were
then re-tested a year later as part of the next year’s annual
health checks.
Data analysis
Baseline 25OHD data
Mean baseline 25OHD levels were analysed using a single
multiple regression analysis. The regression model assessed
the effects of the following categorical predictors on baseline
25OHD levels: season of testing, levels of security, prescrip-
tion of antipsychotic or anticonvulsant medication, and the
cohort tested. Data that were not normally distributed
were transformed appropriately (using a log10 transform-
ation for 25OHD values).
Effect of treatment
Patient records were scrutinised to ascertain whether, fol-
lowing baseline testing, treatment to correct any deficiency
was offered and/or taken. Follow-up testing data were col-
lected, and the McNemar test of marginal homogeneity
was applied to the pairs of non-adjusted 25OHD levels to
assess differences in patients’ 25OHD levels between base-
line and follow-up.
Data were analysed using SPSS version 22.9 This service
evaluation was registered with the Research and Development
department of Northumberland, Tyne and Wear National
Health Service Foundation Trust, in November 2013
(Registration number SER-13-018).
Results
Study population
Seventy-three established patents at Northgate Hospital
had baseline 25OHD screening between January 2013 and
February 2014 (cohort 1). Between January 2013 and
July 2016, a further 27 patients had been admitted to the
hospital and received baseline 25OHD screening on admis-
sion (cohort 2). The two cohorts are described in Tables 1
and 2. As expected, the median length of stay at baseline test
was significantly greater in cohort 1 than in cohort 2 (36
months vs. 1 month; Mann–Whitney U: 34.5, P < 0.001) as
new patients were tested soon after admission. There were
no patients of Black and minority ethnic (BAME) origin
among the patient group.
Baseline vitamin D levels
The mean 25OHD level of the whole study population was
35.1 nmol/L (s.d. 28.1), and the median was 27.0 nmol/L,
Table 1 Description of cohort 1
N Mean age
Sex
Antipsychotics n (%) Anticonvulsants n (%)
Season of test (n)
M F Winter Spring Summer Autumn
Medium security 20 26.5 20 0 9 (45) 8 (40) 5 6 6 3
Low security 39 38.2 30 9 15 (38) 10 (26) 9 7 16 7
Rehabilitation 9 34.0 8 1 4 (44) 2 (22) 0 1 5 3
Autism service 5 33.4 5 0 2 (40) 2 (40) 2 1 2 0
TOTAL 73 34.1 30 22 16 15 29 13
2
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representing positively skewed values (Shapiro–Wilk: 0.699,
P < 0.001). The regression analysis was therefore conducted
using log10-transformed values. The statuses of 100 patients
at baseline are represented in Fig 1, showing that the vast
majority had either deficient or insufficient 25OHD levels.
The regression analysis demonstrated no effect of sea-
son or level of security on the vitamin D status of the patient
at baseline Table 3). Furthermore, there were no differences
between the two cohorts, or between those prescribed anti-
psychotic or anticonvulsant medication.
Therewas a trend for lower 25OHD levels among patients
already prescribed antipsychotic medication, and marginally
higher levels in those on anticonvulsant medication, although
four of the 29 patients in the latter group had already been
prescribed vitamin D supplements. Furthermore, 25OHD
levels were statistically non-significantly higher in the sum-
mer compared with winter (median 25OHD 33 nmol/L vs.
20 nmol/L), and in the rehabilitation service compared with
the medium secure wards (median 25OHD 33.5 nmol/L vs.
27.5 nmol/L).
Follow-up and treatment effects
Follow-up data were available for 89 patients who were
retested around 12 months after baseline screening. The
mean25OHD levelwas66.3 nmol/L (s.d. 33.6) and themedian
was 62.0 nmol/L, which represented a less extreme but still
significant positive skew (Shapiro-Wilk: 0.914, P = 0.035).
The numbers of patients with sufficient and optimal 25OHD
had improved substantially (see Fig 2).
Not all patients who received baseline 25OHD screening
and/or treatment were tested a second time. Some patients
were discharged from hospital in the interim, or their
25OHD level was not requested by the physical treatment
service. A flowchart of all 100 patients is provided in Fig 3.
The regressionanalysiswas repeated for log10-transformed
25OHD levels at follow-up testing. As in the baseline data,
there were no effects for seasonality, security level, or the
prescription of antipsychotic or anticonvulsant medication.
Discussion
This is the first study to report data from a specialist hospital
for patients with IDD who offend, and those with severe aut-
ism spectrum disorders, with a number of levels of secure
and non-secure wards and units. This paper describes rou-
tinely collected data on serum 25OHD levels obtained at
baseline prior to clinical decisions to treat any vitamin D
deficiency, along with follow-up serum levels after a year.
The rationale for the implementation of this protocol was
based on concerns that low levels of sun exposure, the secure
environment and the prescription of psychotropic medica-
tion put in-patients in a ‘high risk’ category, with potentially
serious long-term health sequelae.7
The data suggest considerable vitamin deficiency among
this patient group. Furthermore, there were no clear
Table 2 Description of cohort 2
N Mean age
Sex
Antipsychotics n (%) Anticonvulsants n (%)
Season of test (n)
M F Winter Spring Summer Autumn
Medium security 14 25.8 14 0 3 (21) 2 (14) 2 4 6 2
Low security 11 35.7 9 2 4 (36) 5 (45) 4 1 2 4
Rehabilitation 1 50.0 0 1 1 (100) 0 0 1 0 0
Autism service 1 19.0 1 0 1 (100) 0 0 0 1 0
TOTAL 27 30.5 9 7 6 6 9 6
41 42
10 7
0
10
20
30
40
50
Deficient
<25 nmol/L
Insufficient
25–49
nmol/L
Sufficient
50–74
nmol/L
Optimal >75
nmol/L
Deficient <25 nmol/L
Insufficient 25–49 nmol/L
Sufficient 50–74 nmol/L
Optimal >75 nmol/L
Fig. 1 Vitamin D status of 100 patients at baseline testing.
Table 3 Single multiple regression analysis of between-
subject effects on log10 25OHD levels at baseline
Factor
Log10 25OHD type
III sum of squares d.f.
Mean
square F P-value
Season 0.463 3 0.154 2.354 0.077
Security 0.147 3 0.049 0.746 0.527
Antipsychotics 0.171 1 0.171 2.600 0.110
Anticonvulsants 0.175 1 0.175 2.673 0.106
Cohort 0.089 1 0.089 1.350 0.248
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differences in 25OHD levels between patients already in hos-
pital when baseline screening took place and newly admitted
patients. This might be attributed to deficiencies in the com-
munity, but, in a tertiary service, new admissions frequently
transfer from other in-patient services. Limitations in the
data available mean that further scrutiny is outside the
scope of this paper. There appeared to be a trend for
marginally lower 25OHD levels in secure wards compared
with rehabilitation services, but there was no statistically
significant variation.
Although no significant differences were found between
patients taking psychotropic medication and those who were
not, these factors remain of clinical concern with respect to
bone health. A recent small-scale prospective study found
8
18
34 29
0
10
20
30
40
Deficient
<25 nmol/L
Insufficient
25–49
nmol/L
Sufficient 
50–74
nmol/L
Optimal >75
nmol/L
Deficient <25 nmol/L
Insufficient 25–49 nmol/L
Sufficient 50–74 nmol/L
Optimal >75 nmol/L
Fig. 2 Vitamin D status of 89 patients at follow-up.
BASELINE TESTING INTERVENTION FOLLOW–UP TESTING
Normal 25OHD levels (on
prior treatment) n= 6
Test 1 mean = 103.2 (49.3)
6 continued treatment
Test 2 mean
25OHD = 97.3
(58.3)
MH = 0.908,
P= 0.687
Normal 25OHD levels (no
prior treatment) n= 11
Test 1 mean = 71.2 (28.3)
2 started treatment
Test 1 mean = 103.5
(62.9)
Test 2 mean
25OHD = 67.5
(48.8) 
MH = 1.363,
P= 0.173
9 had no treatment
7 were retested
Test 1 mean = 62.1 (13.1)
Test 2 mean
25OHD = 51.7
(17.5)
MH = 1.364,
P= 0.172
Deficient/insufficient 25OHD
levels (on prior treatment)
n= 2
Test 1 mean = 27.5 (20.5)
2 continued treatment Test 2 mean
25OHD = 77.5
(21.9)
MH = –1.414,
P= 0.157
Deficient/insufficient 25OHD
levels (no prior treatment)
n= 81
Test 1 mean = 25.4 (9.8)
63 started treatment
59 were retested
Test 1 mean = 23.9 (9.4)
Test 2 mean
25OHD = 71.4
(30.0)
MH = –6.444,
P < 0.001
18 had no treatment
13 were retested
Test 1 mean = 27.6 (11.1)
Test 2 mean
25OHD = 35.0
(17.1)
MH = –1.870,
P= 0.062
MH, McNemar’s test of marginal homogeneity for paired non-parametric data.
Fig. 3 Flowchart of 100 patients who underwent baseline screening. Mean (s.d.) 25OHD levels are reported.
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that antipsychotics may inhibit vitamin D-metabolising
enzymes, thereby causing a reduction in both calcium and
25OHD levels.10 This association is of particular concern
given the known link between antipsychotics and osteopor-
osis risk via raised prolactin levels.11
Patients with normal 25OHD levels at baseline who
were already on supplements all opted to continue with
treatment. Those with normal levels at baseline who were
not already receiving treatment were advised by their gen-
eral practitioner based on the clinical scenario. Neither the
supplemented nor the non-supplemented group had signifi-
cant changes in their 25OHD status at follow-up, but num-
bers here were small.
Patients with suboptimal 25OHD levels were all offered
supplementation using a standard protocol. Those who
opted for supplementation had significantly higher 25OHD
levels at follow-up, whereas those who opted out experienced
non-significant changes. As the data here reported are rou-
tinely collected, it is not possible to make any systematic
inference as to what lay behind a patient’s decision to accept
or decline supplementation.
Although vitamin D deficiency was widespread among
this group, it was not present among all patients. There is
some evidence from genome-wide association studies that gen-
etic factors also have a significant role in identifying those at
increased risk, but this is beyond the scope of this evaluation.12
Our data are commensurate with a study of psychiatric
in-patients in a Scottish high-secure hospital at a similar
geographical latitude to Northgate Hospital. That study con-
cluded that all patients in secure settings should be screened
and offered supplementation based on ‘significant and ser-
ious’ deficiency of 25OHD associated with bone demineral-
isation.13 Furthermore, such deficiencies do not appear to
be limited to secure care. One study of people with IDD in
institutionalised nursing care in Finland demonstrated sig-
nificant 25OHD insufficiency, which was addressed by oral
or intramuscular supplementation.14
The data in this study were routinely collected and not
prospectively planned, leading to limitations in their inter-
pretation. Serum parathyroid hormone and calcium levels
were not routinely collected, nor were any bone mineralisa-
tion tests performed. No data on the content or vitamin D
qualities of patients’ diets were collected. It is also not pos-
sible to comment on the longer-term health risks such as
fractures without a larger, more specialised study. The
patient group at Northgate is not ethnically diverse; all
patients in this cohort were of white ethnicity. One study
of a long-stay psychiatric in-patient facility found an associ-
ation between low vitamin D levels and being of a BAME
background, with improvements in 25OHD levels after treat-
ment.15 Another recent study in Tier 4 adolescent psychi-
atric services showed similar numbers of white and BAME
patients with 25OHD deficiency (46 vs. 53%).16
This raises the question as to whether all patients who
are ‘high risk’ should be offered treatment. The long stays
of patients within secure services, along with concomitant
medication, would put these patients within this category.
Current guidance by Public Health England recommends a
minimum of 10 mg per day for the general population aged
four and above, where diet alone is insufficient.5 However,
the choice between simple supplementation or a deficiency
protocol for patients such as these has not been fully estab-
lished. Furthermore, it has not been established whether
supplementation should be offered without suitable baseline
screening. It should also be considered that the more general
effects of vitamin D supplementation are far from certain. A
meta-analysis of 18 randomised controlled trials (RCTs) sug-
gested that there was a modest reduction in overall mortality
for people taking standard doses of 25OHD supplementa-
tion,17 but a more recent umbrella review of systematic
reviews and meta-analyses of observational studies and
RCTs found little convincing evidence of a clear role for vita-
min D in health outcomes.18
Nevertheless, this study has shown that in-patients with
IDD appear to have deficiencies in vitamin D and that these
are amenable to correction by oral supplementation in many
cases. We recommend further research in this area, includ-
ing prospective studies of the longer-term health sequelae.
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